Apr. 2018

New Ivabradine Qualigen

Qualigen launches Ivabradine to treat chronic stable angina pectoris and chronic heart failure

12 April 2018. Qualigen launches Ivabradina 5 mg and 7,5 mg film-coated tablets EFG.

Ivabradina Qualigen EFG is bioequivalent to Procolaran® and is indicated to treat chronic stable angina pectoris and chronic heart failure. 

Ivabradine Qualigen is marketed in presentations of 56 tablets of 5 mg and 7,5 mg.

Ivabradine Qualigen requires a prescription for dispensing and is financed by the Spanish Health System with reduced contribution.

With this launch, Qualigen extends its product portfolio of drugs for the heart failure.